✦ LIBER ✦

P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders

✍ Scribed by Feagan, B.; Sandborn, W.J.; Smyth, M.; Sankoh, S.; Parikh, A.; Fox, I.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mo1222 Effects of Continued Vedolizumab

✍ Feagan, Brian G.; Sandborn, William; Smyth, Michael D.; Sankoh, Serap; Parikh, A 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 343 KB

Mo1217 Effects of Continued Vedolizumab

✍ Sandborn, William J.; Feagan, Brian G.; Reinisch, Walter; Smyth, Michael D.; Xu, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 218 KB

P497 Efficacy of continued vedolizumab t

✍ Sandborn, W.J.; Feagan, B.; Reinisch, W.; Smyth, M.; Xu, J.; Parikh, A.; Fox, I. 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 61 KB

P503 Effectiveness of infliximab as remi

✍ Yokoyama, K.; Kawagishi, K.; Ooka, S.; Mukae, M.; Sada, M.; Kobayashi, K.; Koizu 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 52 KB

P349 The effect of ulcerative colitis (U

✍ D'Haens, G.; Rubin, D.T.; Inglis, S.; Magee, E.; Streck, P.; Solomon, D. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 54 KB

A Model of the Cost Effectiveness of Inf

✍ Farrell, J.; Jiang, Y.; Chaudhary, M.A.; Sheppard, O.; Gathany, T.; Fan, T. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB